Skip to main content
OpenTrials
Completed

NCT Number: NCT01727583

Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients

This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Nestlé CDU / Metabolic Unit

Lausanne, 1000, Switzerland

About this study

In this study, the investigators aim to investigate the effect of various lipid types on GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in nutritional solutions. Moreover, this will allow us to assess whether existing clinical formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI : 19 - 24.9 kg.m-2
  • Normal fasting glycemia
  • Having obtained his informed consent.

Exclusion criteria

  • Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis.
  • Have had a gastrointestinal surgery (with the exception of appendices resection).
  • Malabsorption disorders
  • Lactose intolerance
  • Significant weight loss during the past three months (more than 5% of initial weight)
  • Have a regular consumption of medication
  • Regular supplements (vitamins and minerals) intake during the previous month
  • Have an alcohol intake: > 2 units a day
  • Smoker (more than 2 cigarettes a day)
  • Illicit substances intake, as stated on the medical screening questionnaire
  • Allergy to any food or medication
  • Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges
  • Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
  • Intense physical activity > 3 hours per week
  • Currently participating or having participated in another clinical trial during the past month.
  • Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake

Treatment and study plan

meal intake

Dietary Supplement

Intake of meals characterized by lipid composition

Placebo

Dietary Supplement

Primary outcomes

  1. GLP-2 and GLP-1 kinetics

    Time frame: changes from baseline to 4 hours following meal intake

    GLP-2 and GLP-1 are measured using Elisa

Secondary outcomes

  1. Intestinal and metabolic hormones

    Time frame: Changes from baseline to 4 hours following meal intake

    Those hormones will be measured based on enzymatic technics

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Nov 16, 2012
Registry last updated
Nov 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.